Sai Life Sciences
 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles. (August 2026) |
| NSE: SAILIFE BSE: 544306 | |
| Industry | Pharmaceutical services |
| Founded | 1999 |
| Founder | Krishna Kanumuri |
| Headquarters | |
Key people | Krishna Kanumuri (Executive Chairman) |
| Website | sailife |
Sai Life Sciences Limited is an Indian contract research, development, and manufacturing organisation, headquartered in Hyderabad, Telangana.[1] The company provides drug discovery, development, contract manufacturing services for small-molecule new chemical entities to pharmaceutical and biotechnology companies.[2]
The company was estalished in Hyderabad in January 1999 as Sai Dru Syn Laboratories Limited.[3] It was later renamed Sai Life Sciences Limited. It operates R&D and manufacturing facilities in India, the UK, and the USA.[4]
References
[edit]- ↑ "Indian drugmaker Sai Life Sciences to boost headcount by about 20% amid global demand upswing". Reuters. 20 February 2026. Retrieved 5 August 2026.
- ↑ Buntz, Brian (30 July 2026). "Sai Life Sciences' bet on information-dense scale-up and how it is responding to pharma clients who want acceleration". Drug Discovery & Development. Retrieved 5 August 2026.
- ↑ "Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?". Business Standard. 8 May 2026. Retrieved 5 August 2026.
- ↑ Kumar, Chitranjan (26 August 2025). "Sai Life Sciences shares fall 4% as TPG eyes ₹2,500 cr stake sale via block deals". Fortune India. Retrieved 5 August 2026.
External links
[edit] | This pharmacology-related article is a stub. You can help Wikipedia by adding missing information. |